Medicines Formulary

Medicines A–Z

P

Drug name	NICE TAs	Comments
Pabrinex injection
Paclitaxel	TA55 - Guidance on the use of paclitaxel in the treatment of ovarian cancer TA91 - Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer
Paclitaxel injection	TA214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA284 - Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer	Negative TA
Palbociclib (Ibrance®)	TA495 - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer TA836: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Palforzia®	Palforzia for treating peanut allergy in children and young people (TA769)
Palifermin injection		Private patients only
Paliperidone (Byannli®)		6 monthly injection
Paliperidone (Trevicta®)		Third line option Patient has been stable mentally for at least 12 months and had a stable dose of paliperidone palmitate monthly injection and has not required a dosage adjustment in the last six months 12 months using the monthly injections and no dose adjustment for the last six months before considering the three-monthly injection APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion)
Paliperidone (Xeplion®)		APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
Pancrex V® powder

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.